PTC299
PTC299, a novel, orally administered, small-molecule compound designed to inhibit the production of vascular endothelial growth factor (VEGF) in tumors, is currently in Phase 1b/2 clinical trials in patients with metastatic breast cancer.

For more information on the trial, please visit www.clinicaltrials.gov (Search word: PTC299).